Abstract:Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths in the world. However, there are currently few clinical diagnosis and treatment options available, and there is an urgent need for novel effective approaches. More research is being undertaken on immune-associated cells in the microenvironment because they play a critical role in the initiation and development of HCC. Macrophages are specialized phagocytes and antigen-presenting cells (APCs) that not only directly phagocytose and eliminate tumor cells, but also present tumor-specific antigens to T cells and initiate anticancer adaptive immunity. However, the more abundant M2-phenotype tumor-associated macrophages (TAMs) at tumor sites promote tumor evasion of immune surveillance, accelerate tumor progression, and suppress tumor-specific T-cell immune responses. Despite the great success in modulating macrophages, there are still many challenges and obstacles. Biomaterials not only target macrophages, but also modulate macrophages to enhance tumor treatment. This review systematically summarizes the regulation of tumor-associated macrophages by biomaterials, which has implications for the immunotherapy of HCC.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: the regulation of tumor - associated macrophages (TAMs) in hepatocellular carcinoma (HCC). Specifically, the article explores how to use biomaterials to regulate TAMs to improve the immunotherapy effect of HCC. ### Detailed Explanation: 1. **Background and Importance of the Problem** - Hepatocellular carcinoma (HCC) is the fourth - leading cause of cancer death worldwide, but currently, there are limited diagnostic and treatment options available clinically, and there is an urgent need to develop new and effective methods. - Immune - related cells play a crucial role in the tumor microenvironment, especially macrophages. Macrophages can not only directly phagocytize and eliminate tumor cells but also present tumor - specific antigens to T cells, initiating an anti - cancer adaptive immune response. - However, M2 - type TAMs, which are more abundant at the tumor site, promote tumor escape from immune surveillance, accelerate tumor progression, and inhibit tumor - specific T - cell immune responses. 2. **Research Objectives** - This paper aims to summarize the current strategies for regulating tumor - associated macrophages (TAMs) using biomaterials, especially how to enhance the treatment effect on HCC through these strategies. - Biomaterials can not only target macrophages but also enhance the tumor treatment effect by regulating the function of macrophages. This provides new ideas for the immunotherapy of HCC. 3. **Specific Problems** - How to use biomaterials to regulate the polarization state of TAMs (from M2 - type to M1 - type), thereby enhancing the anti - tumor immune response. - Explore the potential of biomaterials in reducing the number of M2 - type TAMs or inducing their repolarization into M1 - type TAMs. - Study the role of biomaterials in blocking the CD47 - SIRP pathway to enhance the phagocytic activity of macrophages against tumor cells. ### Conclusion: The main purpose of this paper is to provide a new theoretical basis and technical means for the immunotherapy of HCC by summarizing and analyzing the current research progress in regulating TAMs using biomaterials, thereby improving the treatment effect of HCC patients.

Current Strategies for Modulating Tumor-Associated Macrophages with Biomaterials in Hepatocellular Carcinoma

Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy

Macrophages as targets in hepatocellular carcinoma therapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?

Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy

<p>Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives</p>

Targeting tumor-associated macrophages for cancer treatment

Tumor-Associated Macrophages in Tumor Immunity (vol <i>11</i>, <i>583084</i>, <i>2020</i>)

Research advances in tumor-associated macrophages in hepatocellular carcinoma microenvironment

Macrophage-modulating nanomedicine for cancer immunotherapy

Current Strategies for the Treatment of Hepatocellular Carcinoma by Modulating the Tumor Microenvironment via Nano-Delivery Systems: A Review

Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma

Tumor‑associated macrophages activated in the tumor environment of hepatocellular carcinoma: Characterization and treatment (Review)

Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy

Targeting Tumor-Associated Macrophages As an Antitumor Strategy.

Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy

Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer

Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression

Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer

Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress